Introduction
============

Acute kidney injury (AKI) is a frequent and challenging medical complication with a high risk for morbidity and mortality \[[@b1-krcp-38-356]\]. The Kidney Disease: Improving Global Outcomes (KDIGO) group recommended that careful attention be paid to hemodynamic status during the treatment of patients with AKI \[[@b2-krcp-38-356]\] because blood pressure (BP) has been thought to be essential for organ perfusion \[[@b3-krcp-38-356]\].

Regarding the general management of hypertension, a recent randomized controlled trial (Systolic Blood Pressure Intervention Trial \[SPRINT\]) showed that lowering the systolic BP (SBP) to a target goal of \< 120 mmHg resulted in lower rates of fatal and nonfatal major cardiovascular events and death \[[@b4-krcp-38-356]\]. This trial further demonstrated that adverse outcomes progressively and linearly increase with a rise in BP. Subsequently, a BP of \< 120 mmHg has been adopted as optimal in hypertensive patients. However, some data on acute illnesses such as acute coronary syndromes and stroke have suggested too low of a BP may be harmful \[[@b5-krcp-38-356]--[@b8-krcp-38-356]\]. In other words, a J- or U-shaped curve relationship existed between BP and mortality/cardiovascular outcomes.

Most studies considering hemodynamic targets in patients with AKI have been performed in critically ill patients \[[@b9-krcp-38-356]--[@b16-krcp-38-356]\]. Especially in patients with septic AKI or hepatorenal syndrome, a target mean arterial pressure (MAP) of 65 to 70 mmHg has been suggested, while a higher target MAP of 80 to 85 mmHg is recommended in patients with chronic hypertension \[[@b17-krcp-38-356]\].

However, few data cover the subject of optimal BP in noncritically ill patients with AKI relative to mortality or severe AKI, particularly when compared with critically ill patients. We thus sought to analyze the data that do exist to determine the best target range for BP in noncritically ill patients with AKI.

Methods
=======

Study population
----------------

We collected data from 21,572 hospitalized patients aged 18 years or older whose serum creatinine (Cr) levels were identified once or more during their first admission for a period of 1 year (2013) at a tertiary care hospital in Seongnam, Korea. All admissions through general practice, accident, and emergency were included. Among them, 21,172 patients were deemed eligible for this study after excluding those with missing BP data (n = 91), pre-existing end-stage renal disease (n = 309), and intensive care unit admission during hospitalization (n = 3,048). Finally, we enrolled only 1,612 patients diagnosed with AKI according to the KDIGO definition based on serum Cr measurements ([Fig. 1](#f1-krcp-38-356){ref-type="fig"}). All clinical investigations were conducted with respect to the 2008 Declaration of Helsinki and good clinical practice guidelines. This study was approved by the Institutional Review Board (IRB) of Seoul National University Bundang Hospital (IRB number: H-1508-310-115), with no written consent required because patient records/information were anonymized and de-identified prior to analysis.

Measurements and definitions
----------------------------

Demographic, physiological, and laboratory data at the index admission were collected from an electronic medical records database. Serum Cr values were measured via the rate-blanked compensated kinetic alkaline picrate Jaffe kinetic method using an automatic analyzer (Toshiba-200FR; Toshiba Corp., Tokyo, Japan). The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) study equation \[[@b18-krcp-38-356]\] adjusted for a Korean ethnic coefficient \[[@b19-krcp-38-356]\]. To detect AKI, at least two Cr measurements were required: First taken during the baseline time window and a second recorded on a different day during hospital admission. We defined the baseline Cr level using the 6-month Cr data from before patients' admission, as this directly affected the detection and staging of AKI, in the manner as follows: By selecting the lowest Cr value measured less than 90 days prior to admission. If this value was unavailable, the lowest Cr value measured between 90 and 180 days before admission was considered. If this value was also unavailable, the Cr level was estimated using the MDRD study equation \[[@b18-krcp-38-356]\] adjusted for a Korean ethnic coefficient \[[@b19-krcp-38-356]\], assuming that the baseline eGFR was 75 mL/min/1.73 m^2^ \[[@b20-krcp-38-356]\]. Inpatient Cr measurements were defined as those obtained during admission. Using both a baseline and an inpatient Cr value measured on different days, AKI was defined as an increase of 0.3 mg/dL or more in or of 1.5 times or more of the serum Cr, using the serum Cr criteria proposed by the KDIGO \[[@b20-krcp-38-356]\]. Severe AKI was defined as stage III of the KDIGO using the serum Cr criteria (threefold increase in the serum Cr from baseline or increase in serum Cr to 4.0 mg/dL or more). We defined AKI solely based on changes in the measured serum Cr values because urine output data were not consistently available for all inpatients. Bacteremia was elucidated via positive blood culture during hospitalization. BacT/Alert FA and FN bottles (bio-Mérieux, Durham, NC, USA) were used for all blood cultures.

BP measurements were conducted using an electronic sphygmomanometer at the discretion of the nurse during the hospitalization period. For the present analysis, the average SBP was calculated for each patient within 48 hours after the development of AKI. The risk of mortality or severe AKI was then evaluated as a function of BP. BP values were categorized into 10-mmHg increments to determine the association with mortality or severe AKI. Because the average follow-up BP variables represented the effects of BP over a period of time rather than at a single point in time, we considered this to be more important in predicting the outcomes.

We assessed the comorbidities based on the code of the International Classification of Disease, 10th Revision (ICD-10) as follows: cardiovascular disease including angina pectoris (I20), myocardial infarction (I21--I23), ischemic heart disease (I24--I25), and heart failure (I50); cancer (C); cerebrovascular disease (I63--I66); hypertension (I10--I15); and diabetes mellitus (E10--14). The presence of hypertension and diabetes mellitus were also confirmed by the use of antihypertensive medications and antihyperglycemic agents, respectively. Antihypertensive drugs included alpha- and beta-blockers, calcium-channel blockers, renin--angiotensin system inhibitors, and diuretics.

Study outcome
-------------

The composite outcome of 90-day all-cause mortality or severe AKI was considered in this research. We combined 90-day data from the Ministry of Security and Public Administration with our dataset using each individual's unique identifier. Mortality data were obtained until August 31, 2015.

Statistical analysis
--------------------

Continuous variables were expressed as means ± standard deviations, while categorical variables were expressed as percentages. Differences in continuous variables were analyzed using one-way analysis of variance or the Kruskal--Wallis rank test, whereas chi-square tests and Fisher's exact test were used for categorical variables. Cox's hazard proportion analysis was used to estimate the hazard ratios (HRs) for composite outcome according to the average SBP. We conducted the tests of proportional hazards assumptions and restricted cubic spline curves, respectively. The HRs and 95% confidence intervals (CIs) for the composite outcomes were calculated after a stepwise adjustment for multiple confounders including age, gender, body mass index, Charlson's comorbidity index, hypertension, operation, bacteremia, white blood cell count, hemoglobin, albumin, cholesterol, alanine aminotransferase, sodium, total CO~2~, and maximal Cr during admission.

The adjusted HR for each category of SBP was calculated based on the BP group in which the event rate was lowest, for which the HR was considered as 1. *P* values of less than 0.05 were considered to be statistically significant. All analyses and calculations were conducted using the IBM SPSS Statistics version 24.0 (IBM Corp., Armonk, NY, USA) and STATA version 14.0 (StataCorp LP, College Station, TX, USA) software programs.

Results
=======

Study population
----------------

Among the 1,612 patients, the mean age, Charlson's comorbidity index value, and serum Cr levels at baseline were 65.8 ± 16.0 years, 2.8 ± 2.2, and 1.00 ± 1.09 mg/dL, respectively. The average SBP/diastolic BP (DBP) within 48 hours after admission and within 48 hours after AKI were 125.8/69.9 mmHg and 123.8/68.3 mmHg, respectively. Of the 1,612 patients, 55.4% were males, 30.1% had hypertension, and 35.6% had diabetes mellitus. The median duration of AKI development was 1.0 (interquartile range: 0--4.0) days after hospital admission. Additionally, the median duration of hospital stay and mean duration of total follow-up were 9.0 (interquartile range: 5--16) and 76.7 days, respectively. In total, 467 patients (29.0%) underwent an operation and 133 patients (8.3%) suffered from bacteremia episodes during admission ([Table 1](#t1-krcp-38-356){ref-type="table"}).

[Table 2](#t2-krcp-38-356){ref-type="table"} shows the demographic and baseline characteristics according to SBP categories within 48 hours after AKI. Patients with low SBP were younger and leaner; less likely to have previous hypertension; had high levels of total bilirubin but low levels of baseline Cr, hemoglobin, albumin, cholesterol, and total CO~2~; and had a high incidence of bacteremia.

Outcomes
--------

Among the 1,612 patients, 90-day mortality rate, severe AKI rate, and composite outcome rate for AKI inpatients were 11.5% (n = 185), 10.1% (n = 163), and 18.7% (n = 302), respectively.

In the composite outcome group, a higher proportion of patients had diabetes mellitus and cancer as compared with in the group without the composite outcome. Additionally, the composite outcome group was older, leaner; had a higher white blood cell count and maximal Cr level during admission but low levels of albumin, sodium, total CO~2~, and hemoglobin; and had a high incidence of bacteremia and low incidence of operation. The relationship between SBP and composite outcome followed a U-shaped curve, with an increased event rate at both low and high SBP values ([Fig. 2](#f2-krcp-38-356){ref-type="fig"}, [3](#f3-krcp-38-356){ref-type="fig"}). The average SBP after AKI predicted the composite outcome after adjusting for baseline variables (reference SBP: 120--129 mmHg; \< 100 mmHg: HR 1.84, *P* = 0.015; 100--109 mmHg: HR 1.56, *P* = 0.038; 110--119 mmHg: HR 1.15, *P* = 0.483; 130-- 139 mmHg: HR 1.51, *P* = 0.045; ≥ 140 mmHg: HR 1.73, *P* = 0.005). The curve was relatively flat for SBPs of 110 to 130 mmHg after AKI ([Table 3](#t3-krcp-38-356){ref-type="table"}). Separately, bias-corrected confidence intervals using bootstrap analysis (n = 10,000) to validate the SBP groups after AKI in predicting composite outcomes were calculated (reference SBP: 120--129 mmHg; \< 100 mmHg, 1.047--3.246; 100--109 mmHg, 1.014--2.391; 110--119 mmHg, 0.770--1.721; 130--139 mmHg, 0.972--2.360; and ≥ 140 mmHg, 1.063--2.829).

Subgroup analysis
-----------------

We performed a subgroup analysis according to the underlying disease to evaluate the effects of BP categories on the composite outcome in patients with AKI. [Supplementary Tables 1 and 2](#s1-krcp-38-356){ref-type="supplementary-material"} (available online) display the relation between BP and composite outcomes across the patient comorbidities. In 485 hypertensive patients, the proportion taking antihypertensive medication is shown in [Table 1](#t1-krcp-38-356){ref-type="table"}. In these patients, the risk of composite outcome increased 2.5-fold in the group with SBPs of less than 100 mmHg as compared with the reference group (SBP of 120--129 mmHg). In contrast, the relationship between SBP and composite outcome significantly followed a J-shaped curve, with an increased event rate observed at high SBP values in the nonhypertensive patients (reference SBP: 120--129 mmHg; 130--139 mmHg: HR 2.125; 95% CI, 1.301--3.469; ≥ 140 mmHg: HR 2.485; 95% CI, 1.489--4.147).

Diabetic patients showed a similar pattern of BP and composite outcome as that of nonhypertensive patients. In nondiabetic patients, the risk of composite outcome increased 2.1-fold in the group with SBPs of less than 100 mmHg in comparison with the reference group (SBP 120--130 mmHg). A difference in the relationship between SBP and the composite outcome was observed, depending on the underlying disease.

Discussion
==========

The main finding of this study was that the average SBP within 48 hours after AKI was a predictor for the composite outcome in noncritically ill hospitalized patients. After AKI, a U-shaped curve association was observed between the average SBP within 48 h after AKI and composite outcome, with the lowest event rates noted in the SBP range of approximately 110 to 129 mmHg.

The ideal target BP has been controversial in the general management of hypertension. Prior to the publication of SPRINT, the international guidelines for hypertension recommended a BP of below 140/90 mmHg was optimal in most patients with hypertension \[[@b21-krcp-38-356]--[@b23-krcp-38-356]\]. However, as a more recent randomized controlled trial, SPRINT showed that an SBP of less than 120 mmHg as compared with of less than 140 mmHg in patients with hypertension but without diabetes resulted in lower rates of fatal and nonfatal major cardiovascular events and death \[[@b4-krcp-38-356]\]. Therefore, a recent international guideline reported that a BP target of less than 130/80 mmHg is indicated \[[@b24-krcp-38-356],[@b25-krcp-38-356]\].

Meanwhile, several studies have reported that too low of a BP may be harmful in patients with AKI as in those with acute illnesses such as acute coronary syndrome and stroke \[[@b5-krcp-38-356]--[@b8-krcp-38-356],[@b10-krcp-38-356]--[@b12-krcp-38-356],[@b16-krcp-38-356],[@b17-krcp-38-356]\]. Therefore, in patients with septic AKI or hepatorenal syndrome, a target MAP of 65 to 70 mmHg is suggested. A higher target MAP of 80 to 85 mmHg is also suggested in patients with chronic hypertension \[[@b17-krcp-38-356]\]. However, most studies on hemodynamic targets in patients with AKI have been conducted in critically ill patients \[[@b9-krcp-38-356]--[@b16-krcp-38-356]\]. Although Liu et al \[[@b26-krcp-38-356]\] reported that relative decreases in SBP and DBP and MAP were associated with the development of AKI and a decrease in SBP is a significant independent predictor of the development of severe AKI in noncritically ill patients, there is limited knowledge concerning the optimal BP in general ward patients with AKI. To our knowledge, this is the first study to investigate the hemodynamic target in noncritically ill ward patients with AKI relative to severe AKI or mortality. As this study was based on general ward hospitalization, with the exception of high-risk AKI in critically ill patients, it could give physicians realistic guidance for treating hospitalized patients. Furthermore, internal validation was performed using bootstrap analysis, and the prediction models used might be robust.

Our data showed that a U-shaped curve association existed between the average SBP within 48 hours after AKI and a composite outcome, with the lowest event rates present in the SBP range of approximately 110 to 129 mmHg in these patients after the development of AKI. Importantly, however, the present study does not prove a causal relationship between low/high BP and clinical outcomes because of its retrospective nature. Instead, a U-shaped curve association between the average SBP after AKI and the composite outcome can be inferred as follows: In accordance with previous studies \[[@b10-krcp-38-356],[@b11-krcp-38-356]\], too low of a BP can be associated with poor prognosis because BP has been thought to be essential for organ perfusion \[[@b3-krcp-38-356]\]. We thought that normotensive ischemic AKI may be a cause of severe AKI in patients with normal-range or high BP after AKI \[[@b26-krcp-38-356],[@b27-krcp-38-356]\].

MAP has been widely used as an index for optimal BP and, recently, mean perfusion pressure calculated together with central venous pressure was introduced as a more useful indicator in the context of preventing AKI \[[@b3-krcp-38-356],[@b28-krcp-38-356]\]. Our data showed that only SBP was an independent predictor of the clinical outcome; DBP and MAP were not predictors (data not shown). A previous study of noncritically ill ward patients suggested that only SBP is an independent predictor of the development of severe AKI \[[@b26-krcp-38-356]\], which is consistent with our data. Moreover, noncritically ill ward patients cannot measure the mean perfusion pressure or central venous pressure, which is known to better reflect renal perfusion than MAP does.

We further analyzed the association between SBP and clinical outcomes, adjusting antihypertensive medications to the existing variables in 485 hypertensive patients. The HR showed a similar pattern, but there was no correlation between SBP and the composite outcome (data not shown). The reason for losing statistical significance is presumed to be that the multivariate analysis included too many variables as compared with the 485 patients after adjusting antihypertensive agents to the existing variables. In terms of antihypertensive therapy, the use of renin--angiotensin receptor blockade or beta-blockers was associated with favorable outcomes (HR 0.44, *P* = 0.001 and HR 0.43, *P* = 0.006), while diuretics were associated with a poor prognosis (HR 1.74; *P* = 0.021).

Our study has several limitations. First, it is a retrospective analysis of a heterogeneous population with different comorbidities admitted to a single tertiary hospital. Therefore, the results of our findings cannot be generalized. We also cannot prove a causal relationship between BP and the clinical outcomes. Therefore, we only mentioned the association between BP and the outcomes; further prospective research is needed to prove causality. Furthermore, we cannot determine the exact etiology of AKI and the causes of death because we did not have sufficient data. Fourth, with regard to defining AKI, we did not consider time (within 48 hours or 7 days) according to the guidelines proposed by the KDIGO \[[@b20-krcp-38-356]\]; however, the majority of AKI episodes occurred during the early period of hospitalization (within 7 days) \[[@b29-krcp-38-356]\]. Fifth, with regard to the definition of AKI, if the Cr value measured at less than 180 days prior to admission was unavailable, the Cr level was estimated using the MDRD study equation adjusted for the Korean ethnic coefficient, assuming that the baseline eGFR was 75 mL/min/1.73 m^2^. Although this approach has been used in prior research \[[@b30-krcp-38-356]--[@b39-krcp-38-356]\] as well as studies of AKI epidemiology using the RIFLE (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease) protocol and has recently been validated \[[@b40-krcp-38-356]\], this assumption was applied to only 25.6% of patients.

In conclusion, we performed a retrospective cohort study on noncritically ill patients who developed AKI and found that a U-shaped curve association existed between the average SBP within 48 hours after AKI and a composite outcome, with the lowest event rates found in the SBP range of approximately 110 to 129 mmHg.
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###### 

Baseline characteristics of patients with AKI

  Characteristic                                      Total (n = 1,612)
  --------------------------------------------------- -------------------
  Average blood pressure (mmHg)                       
   SBP within 48 hours after admission                125.8 ± 16.2
   DBP within 48 hours after admission                69.9 ± 10.1
   SBP within 48 hours after the development of AKI   123.8 ± 16.3
   DBP within 48 hours after the development of AKI   68.3 ± 10.4
  Demographics                                        
   Sex, male                                          893 (55.4)
   Age (yr)                                           65.8 ± 16.0
   Body mass index (kg/m^2^)                          23.3 ± 3.9
  Comorbidity                                         
   Charlson's comorbidity index                       2.8 ± 2.2
   Hypertension                                       485 (30.1)
   Diabetes mellitus                                  574 (35.6)
  Medication                                          
   RAAS blockade                                      222 (13.8)
   Beta-blocker                                       143 (8.9)
   Calcium-channel blocker                            198 (12.3)
   Diuretics                                          224 (13.9)
   Alpha-blocker                                      24 (1.5)
  Laboratory values                                   
   Creatinine at baseline (mg/dL)                     1.00 ± 1.09
   Creatinine at admission (mg/dL)                    1.57 ± 1.72
   WBC (10^9^/L)                                      10.0 ± 16.9
   Hemoglobin (g/L)                                   114.8 ± 23.0
   Albumin (g/L)                                      35.9 ± 6.3
   Glucose (mmol/L)                                   8.0 ± 4.1
   Bilirubin, total (μmol/L)                          21.6 ± 53.2
   Cholesterol, total (mmol/L)                        4.1 ± 1.4
   Na (mmol/L)                                        137.5 ± 4.8
   K (mmol/L)                                         4.2 ± 0.7
   Total CO~2~ (mmol/L)                               22.9 ± 3.8
  Operation                                           467 (29.0)
  Sepsis                                              133 (8.3)

Data are presented as mean ± standard deviation or number (%).

AKI, acute kidney injury; DBP, diastolic blood pressure; RAAS, renin--angiotensin--aldosterone system; SBP, systolic blood pressure; WBC, white blood cell.

###### 

Demographic baseline characteristics by average SBP categories after AKI

                                     Mean SBP (mmHg)   *P* value                                                                  
  ---------------------------------- ----------------- -------------- -------------- -------------- -------------- -------------- ----------
  Demographics                                                                                                                    
   Sex, male                         37 (43.5)         108 (48.6)     229 (57.3)     234 (59.8)     128 (50.6)     157 (60.2)     0.396
   Age (yr)                          62.8 ± 16.6       63.8 ± 15.9    64.3 ± 16.1    66.4 ± 16.7    68.3 ± 14.3    67.3 ± 15.8    0.002
   Body mass index (kg/m^2^)         21.1 ± 4.4        22.8 ± 3.7     23.1 ± 3.8     23.4 ± 4.0     23.5 ± 3.9     24.3 ± 4.1     \< 0.001
  Comorbidity                                                                                                                     
   Charlson's comorbidity index      3.0 ± 2.3         3.1 ± 2.3      2.8 ± 2.3      2.6 ± 2.1      2.8 ± 2.3      2.6 ± 2.3      0.114
   Hypertension                      21 (24.7)         58 (26.1)      106 (26.5)     120 (30.7)     68 (26.9)      112 (42.9)     \< 0.001
   Diabetes mellitus                 26 (30.6)         81 (36.5)      128 (32.0)     117 (29.9)     99 (39.1)      123 (47.1)     0.001
  Medication                                                                                                                      
   RAAS blockade                     10 (11.8)         27 (12.2)      51 (12.8)      58 (14.8)      35 (13.8)      41 (15.7)      0.803
   Beta-blocker                      3 (3.5)           15 (6.8)       30 (7.5)       38 (9.7)       24 (9.5)       33 (12.6)      0.069
   Calcium-channel blocker           4 (4.7)           20 (9.0)       39 (9.8)       46 (11.8)      27 (10.7)      62 (23.8)      \< 0.001
   Diuretics                         13 (15.3)         30 (13.5)      49 (12.3)      57 (14.6)      31 (12.3)      44 (16.9)      0.592
   Alpha-blocker                     0 (0)             3 (1.4)        3 (0.8)        3 (0.8)        6 (2.4)        9 (3.4)        0.030
  Laboratory values                                                                                                               
   Creatinine at baseline (mg/dL)    0.86 ± 1.29       0.82 ± 0.62    0.87 ± 0.56    0.93 ± 0.76    1.11 ± 1.44    1.41 ± 1.68    \< 0.001
   Creatinine at admission (mg/dL)   1.39 ± 2.04       1.18 ± 0.89    1.29 ± 1.02    1.38 ± 1.14    1.63 ± 1.74    2.64 ± 2.89    \< 0.001
   WBC (10^9^/L)                     11.1 ± 12.3       10.1 ± 9.8     11.0 ± 27.5    9.2 ± 5.3      8.8 ± 7.5      10.6 ± 19.3    0.484
   Hemoglobin (g/L)                  106.9 ± 19.6      112.3 ± 18.8   115.2 ± 23.3   118.1 ± 22.9   115.9 ± 23.1   113.1 ± 25.8   \< 0.001
   Albumin (g/L)                     32.3 ± 7.0        34.5 ± 6.4     36.1 ± 6.0     36.8 ± 6.0     36.5 ± 6.1     35.8 ± 6.5     \< 0.001
   Glucose (mmol/L)                  8.1 ± 4.8         8.0 ± 3.8      8.3 ± 4.4      7.4 ± 3.2      7.8 ± 3.4      8.5 ± 5.3      0.032
   Bilirubin, total (μmol/L)         44.2 ± 104.8      25.1 ± 59.5    25.2 ± 60.1    19.1 ± 46.5    16.2 ± 30.3    14.8 ± 28.9    \< 0.001
   Cholesterol, total (mmol/L)       3.9 ± 2.6         3.8 ± 1.3      4.1 ± 1.4      4.1 ± 1.3      4.2 ± 1.2      4.4 ± 1.4      \< 0.001
   Na (mmol/L)                       136.5 ± 6.5       137.3 ± 5.2    137.0 ± 4.6    138.0 ± 4.8    137.9 ± 4.2    137.7 ± 4.5    0.011
   K (mmol/L)                        4.2 ± 0.8         4.2 ± 0.6      4.2 ± 0.6      4.2 ± 0.6      4.2 ± 0.6      4.4 ± 0.8      0.018
   Total CO~2~ (mmol/L)              22.4 ± 4.9        23.3 ± 3.6     23.1 ± 3.9     23.3 ± 3.6     22.7 ± 3.8     22.1 ± 3.5     \< 0.001
  Operation                          19 (22.4)         65 (29.3)      128 (32.0)     120 (30.7)     61 (24.1)      74 (28.4)      0.212
  Sepsis                             13 (15.3)         23 (10.4)      41 (10.3)      28 (7.2)       17 (6.7)       11 (4.2)       0.007

Data are presented as number (%) or mean ± standard deviation.

AKI, acute kidney injury; RAAS, renin--angiotensin--aldosterone system; SBP, systolic blood pressure; WBC, white blood cell.

###### 

Adjusted hazard ratios for composite outcome according to average SBP

  Cox proportional hazards model                            Composite outcome rate (n/total n, %)   HR      95% CI         *P* value
  --------------------------------------------------------- --------------------------------------- ------- -------------- -----------
  SBP within 48 hours after the development of AKI (mmHg)                                                                  
   \< 100                                                   27/85 (31.8)                            1.843   1.124--3.025   0.015
   100--109                                                 47/222 (21.2)                           1.557   1.025--2.363   0.038
   110--119                                                 62/400 (15.5)                           1.151   0.777--1.705   0.483
   120--129                                                 52/391 (13.3)                           1       Reference      
   130--139                                                 49/253 (19.4)                           1.514   1.008--2.274   0.045
  ≥ 140                                                     65/261 (24.9)                           1.734   1.177--2.555   0.005

Multivariable, adjusted for age, gender, body mass index, Charlson's comorbidity index, hypertension, operation, bacteremia, white blood cell count, hemoglobin, albumin, cholesterol, alanine aminotransferase, sodium, total CO~2~, and maximal creatinine during admission.

AKI, acute kidney injury; CI, confidence interval; HR, hazard ratio; SBP, systolic blood pressure.
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